BRIUMVI data presented by TG Therapeutics on October 21, 2026, showed that approximately 88% of patients continuously treated with the multiple sclerosis drug remained free from confirmed disability progression through seven years. The company also disclosed research on alternative administration approaches at the 10th Joint ACTRIMS-ECTRIMS Meeting, known as MSToronto2026.
Key Takeaways
- Seven-year ULTIMATE I and II follow-up focused on disability outcomes in continuously treated patients.
- Subcutaneous dosing and simplified intravenous administration remain research approaches, not newly approved regimens.
- The conference program also included real-world BRIUMVI evidence and early-stage azer-cel research.
Table of Contents
- BRIUMVI data extend the long-term treatment picture
- Administration studies explore alternatives to current dosing
- Real-world evidence and azer-cel broaden the program
- Conclusion
BRIUMVI data extend the long-term treatment picture
TG Therapeutics’ central disclosure concerned follow-up from the pivotal ULTIMATE I and II trials. The approximately 88% figure applies specifically to patients who received BRIUMVI continuously, rather than every patient originally enrolled in the studies.
The finding addresses durability of treatment benefit, an important question for a therapy used in a chronic disease. It should not be interpreted as a cure rate or as evidence that every aspect of multiple sclerosis remained unchanged.
BRIUMVI, also known as ublituximab-xiiy, is an anti-CD20 monoclonal antibody and the company’s main commercial treatment. The conference update was a clinical development disclosure, not an earnings announcement.
| Item | Details |
|---|---|
| ULTIMATE I and II | Pivotal trial follow-up assessing long-term BRIUMVI outcomes. |
| ENHANCE | Phase 3 research into simplified intravenous administration. |
| ENABLE | Real-world evidence on tolerability and patient satisfaction. |
| Azer-cel | Phase 1 research in primary progressive multiple sclerosis. |
Administration studies explore alternatives to current dosing
The company’s BRIUMVI dosing information describes a one-hour intravenous infusion twice yearly following the starting dose. That established schedule provides the baseline for understanding the administration approaches discussed at the meeting.
Phase 1 findings explored subcutaneous administration that could enable quarterly dosing. Separately, Phase 3 ENHANCE results suggested the possibility of simplifying intravenous treatment to a single infusion.
These studies address how treatment might be delivered, rather than establishing a newly approved schedule. The potential convenience of either approach remains distinct from regulatory authorization and routine commercial availability.
Real-world evidence and azer-cel broaden the program
TG Therapeutics also presented ENABLE real-world evidence concerning BRIUMVI tolerability and patient satisfaction. Those measures add information about treatment experience outside the pivotal trial program, but are different from the long-term disability endpoint.
A late-breaking oral presentation covered a Phase 1 trial of azer-cel in patients with primary progressive multiple sclerosis. This is a separate early-stage research program, not an extension of BRIUMVI’s approved indication.
Conclusion
The update combines longer-term BRIUMVI outcomes with research into delivery options and a separate early-stage MS treatment. The development programs to watch are subcutaneous BRIUMVI, ENHANCE and azer-cel; the supplied disclosures do not establish a date for their next results or any new regulatory approval.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
